RESUMO
The mechanisms through which the oncoprotein c-Myc initiates locus-specific gene amplification are not understood. When analysing the initiation mechanism of c-Myc-dependent amplification of the mouse ribonucleotide reductase R2 (R2) gene, we observe c-Myc-dependent initiation of illegitimate DNA replication of the R2 gene. We demonstrate multiple simultaneous c-Myc-induced R2 replication forks, whereas R2 normally replicates with a single fork. In contrast, cyclin C replicates with only a single replication fork irrespective of c-Myc deregulation. In addition to de novo replication forks, c-Myc also initiates bi-allelic replication of R2, abrogating its normal mono-allelic replication pattern. Moreover, several chromosomal regions also display c-Myc-induced illegitimate replication profiles. Thus, c-Myc can act as an illegitimate replication-licensing factor that promotes de novo replication initiation and illegitimate replication timing that adversely impacts upon genomic stability.
Assuntos
Proteínas Proto-Oncogênicas c-myc/fisiologia , Recombinação Genética/fisiologia , Ribonucleosídeo Difosfato Redutase/genética , Fatores de Transcrição , Alelos , Animais , Fatores de Transcrição de Zíper de Leucina e Hélice-Alça-Hélix Básicos , Fatores de Transcrição de Zíper de Leucina Básica , Bromodesoxiuridina/análise , Ciclo Celular/genética , Células Cultivadas , Bandeamento Cromossômico , Cromossomos/genética , Cromossomos/ultraestrutura , Ciclina C , Ciclinas/genética , Replicação do DNA/fisiologia , Proteínas de Ligação a DNA/química , Dimerização , Eletroforese em Gel Bidimensional , Ensaio de Desvio de Mobilidade Eletroforética , Amplificação de Genes , Regulação da Expressão Gênica , Genes myc , Células-Tronco Hematopoéticas/efeitos dos fármacos , Células-Tronco Hematopoéticas/metabolismo , Humanos , Camundongos , Índice Mitótico , Ligação Proteica , Proteínas Proto-Oncogênicas c-myc/química , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/fisiologia , Recombinação Genética/genética , Sequências Reguladoras de Ácido Nucleico , TransfecçãoRESUMO
We examined the expression of cyclins D1, D2, D3, and E in mouse B-lymphocytic tumors. Cyclin D2 mRNA was consistently elevated in plasmacytomas, which characteristically contain Myc-activating chromosome translocations and constitutive c-Myc mRNA and protein expression. We examined the nature of cyclin D2 overexpression in plasmacytomas and other tumors. Human and mouse tumor cell lines that exhibited c-Myc dysregulation displayed instability of the cyclin D2 gene, detected by Southern blot, fluorescent in situ hybridization (FISH), and in extrachromosomal preparations (Hirt extracts). Cyclin D2 instability was not seen in cells with low levels of c-Myc protein. To unequivocally demonstrate a role of c-Myc in the instability of the cyclin D2 gene, a Myc-estrogen receptor chimera was activated in two mouse cell lines. After 3 to 4 days of Myc-ER activation, instability at the cyclin D2 locus was seen in the form of extrachromosomal elements, determined by FISH of metaphase and interphase nuclei and of purified extrachromosomal elements. At the same time points, Northern and Western blot analyses detected increased cyclin D2 mRNA and protein levels. These data suggest that Myc-induced genomic instability may contribute to neoplasia by increasing the levels of a cell cycle-regulating protein, cyclin D2, via intrachromosomal amplification of its gene or generation of extrachromosomal copies.
Assuntos
Ciclinas/genética , Genes myc , Animais , Northern Blotting , Southern Blotting , Mapeamento Cromossômico , Cromossomos , Ciclina D2 , Amplificação de Genes , Humanos , Hibridização in Situ Fluorescente , Camundongos , Células Tumorais CultivadasRESUMO
The c-Myc oncoprotein is highly expressed in malignant cells of many cell types, but the mechanism by which it contributes to the transformation process is not fully understood. Here, we show for the first time that constitutive or activated overexpression of the c-myc gene in cultured mouse B lymphocytes is followed by chromosomal and extrachromosomal amplification as well as rearrangement of the ribonucleotide reductase R2 gene locus. Electron micrographs and fluorescent in situ hybridization (FISH) demonstrate the c-Myc-dependent generation of extrachromosomal elements, some of which contain R2 sequences. However, unlike other genes that have been shown to be targets of c-Myc-dependent genomic instability, amplification of the R2 gene is not associated with alterations in R2 mRNA or protein expression. These data suggest that c-Myc-dependent genomic instability involves a greater number of genes than previously anticipated, but not all of the genes that are amplified in this system are transcriptionally upregulated.
Assuntos
Proteínas Proto-Oncogênicas c-myc/metabolismo , Ribonucleotídeo Redutases/genética , Animais , Linfócitos B/enzimologia , Southern Blotting , Hibridização in Situ Fluorescente , Camundongos , Microscopia Eletrônica , Transcrição GênicaRESUMO
Here, we describe a gentle and effective method for the rapid and reproducible isolation of histone-bound extrachromosomal DNA molecules called extrachromosomal elements (EEs). This method facilitates the harvest of a specific population of EEs following their isolation from cultured cells, primary tissues, and tumor cells. Active EEs are bound to histone proteins, and these histone-bound EEs carry actively transcribing genes such as c-myc. Our method exploits the presence of histones on EEs and serves as a first-step purification procedure, allowing for the cloning or multivariant analysis of an immunopurified sample of EEs. We isolated EEs from 4-hydroxytamoxifen (4-HT)-activated Myc-ER-regulatable Pre-B ABM cells. Following one round of immunoprecipitation, we demonstrate the purification of histone-bound EEs. We confirmed that our purification enriched for EEs that carry genes by fluorescent in situ hybridization of EEs (FISH-EEs), and we probed non-enriched and immunopurified EEs with a dihydrofolate reductase (DHFR) cDNA probe that is known to detect extrachromosomal amplification in Myc-activated cells. We demonstrate the enrichment of immunoprecipitated DHFR-containing extrachromosomal DNA molecules.
Assuntos
DNA/isolamento & purificação , Herança Extracromossômica , Histonas/isolamento & purificação , Técnicas de Imunoadsorção , Animais , Anticorpos/metabolismo , Linhagem Celular , DNA/metabolismo , Fluoresceína-5-Isotiocianato , Corantes Fluorescentes , Histonas/imunologia , Histonas/metabolismo , Hibridização in Situ Fluorescente , Indóis , Camundongos , Proteínas do Tecido Nervoso , Proteínas Proto-Oncogênicas c-myc/genética , Sefarose , Tetra-Hidrofolato Desidrogenase/genéticaRESUMO
A series of twelve structurally related bisdioxopiperazines that included ICRF-187 (dexrazoxane), ICRF-159 (razoxane), ICRF-193, and ICRF-154 were examined both for their ability to inhibit the growth of Chinese hamster ovary (CHO) cells and their ability to inhibit the catalytic activity of mammalian DNA topoisomerase II. The bisdioxopiperazines exhibited a wide range in both growth inhibitory effects (30,000-fold), and in their ability to inhibit the catalytic activity of topoisomerase II (150-fold). The cytotoxicity of the bisdioxopiperazines toward CHO cells was highly correlated (correlation coefficient r = 0.86, P = 0.0003) with their inhibition of the catalytic activity of DNA topoisomerase II. This result strongly suggests that DNA topoisomerase II is the functional target of the bisdioxopiperazines. The stereoisomers (+)-ICRF-187 and (-)-ICRF-186 were observed to be equally cytotoxic and equally inhibitory toward DNA topoisomerase II. This result indicates that the bisdioxopiperazine binding site on DNA topoisomerase II is large enough or flexible enough to accommodate either form of the drug. The strongly metal-ion binding fully rings-opened hydrolysis product of ICRF-187, ADR-925, demonstrated no measurable inhibitory activity toward DNA topoisomerase II or cytotoxicity toward CHO cells.
Assuntos
Antineoplásicos/farmacologia , Citotoxinas/farmacologia , Razoxano/análogos & derivados , Inibidores da Topoisomerase II , Animais , Células CHO , Cricetinae , Células L , Camundongos , Análise de Regressão , Relação Estrutura-AtividadeRESUMO
A Chinese hamster ovary (CHO) cell line highly resistant to the non-cleavable complex-forming topoisomerase II inhibitor dexrazoxane (ICRF-187, Zinecard) was selected. The resistant cell line (DZR) was 1500-fold resistant (IC50 = 2800 vs 1.8 microM) to continuous dexrazoxane exposure. DZR cells were also cross-resistant (8- to 500-fold) to other bisdioxopiperazines (ICRF-193, ICRF-154, and ICRF-186), and somewhat cross-resistant (4- to 14-fold) to anthracyclines (daunorubicin, doxorubicin, epirubicin, and idarubicin) and etoposide (8.5-fold), but not to the other non-cleavable complex-forming topoisomerase II inhibitors suramin and merbarone. The cytotoxicity of dexrazoxane to both cell lines was unchanged in the presence of the membrane-active agent verapamil. DZR cells were 9-fold resistant to dexrazoxane-mediated inhibition of topoisomerase II DNA decatenation activity compared with CHO cells (IC50 = 400 vs 45 microM), but were only 1.4-fold (IC50 = 110 vs 83 microM) resistant to etoposide. DZR cells contained one-half the level of topoisomerase II protein compared with parental CHO cells. However, the specific activity for decatenation using nuclear extract topoisomerase II was unchanged. Etoposide (100 microM)-induced topoisomerase II-DNA complexes in DZR cells and isolated nuclei were similarly one-half the level found in CHO cells and in isolated nuclei. However, the ability of 500 microM dexrazoxane to inhibit etoposide (100 microM)-induced topoisomerase II-DNA covalent complexes was reduced 4- to 6-fold in both DZR cells and nuclei compared with CHO cells and nuclei. In contrast, there was no differential ability of aclarubicin or merbarone to inhibit etoposide-induced topoisomerase II-DNA complexes in CHO compared with DZR cells and isolated nuclei. It was concluded that the DZR cell line acquired its resistance to dexrazoxane mainly through an alteration in the topoisomerase II target.
Assuntos
Células CHO/efeitos dos fármacos , Razoxano/toxicidade , Inibidores da Topoisomerase II , Aclarubicina/farmacologia , Animais , Cricetinae , DNA Topoisomerases Tipo II/genética , Resistência a Medicamentos , Etilenodiaminas/toxicidade , Etoposídeo/antagonistas & inibidores , Etoposídeo/farmacologia , Glicina/análogos & derivados , Glicina/toxicidade , Mutação , Tiobarbitúricos/farmacologia , Verapamil/farmacologiaRESUMO
Previously, we determined that elimination of deoxycytidylate (dCMP) deaminase (DCD1) in the yeast Saccharomyces cerevisiae increases the intracellular dCTP:dTTP ratio and reduces the induction of G x C --> A x T transitions in the SUP4-o gene by ethyl methanesulfonate (EMS) and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Simultaneously, the G x C --> C x G transversion frequency rises substantially. We attributed the first response to dCTP outcompeting dTTP for incorporation opposite O6-alkylguanine, and the second outcome to the increased dCTP pool causing error-prone repair of apurinic (AP) sites resulting from the removal or lability of N7-alkylguanine. To test the latter hypothesis, we used isogenic dcd1 strains deleted for either of two genes (MAG1: 3-methyladenine glycosylase; APN1: apurinic endonuclease) involved in the repair of N7-alkylguanine. In these backgrounds, EMS or MNNG induction of total SUP4-o mutations, G x C --> A x T transitions and G x C --> C x G transversions were reduced by >98%, >97%, and >80%, respectively. Mutation frequencies in the dcd1 apn1 strain were close to those for spontaneous mutagenesis in the wild-type parent. These findings argue that misincorporation of dCTP during repair of alkylation-induced AP sites is responsible for the increased G x C --> C x G transversion frequency in the dcd1 strain treated with EMS or MNNG. The data also demonstrate that defective repair of AP sites coupled with an elevated dCTP:dTTP ratio eliminates most EMS and MNNG mutagenesis. In addition, the results point to a role for AP sites in the production of some EMS- and MNNG-induced G x C --> A x T transitions as well as other substitutions in the dcd1 strain.
Assuntos
Alquilantes/toxicidade , Carbono-Oxigênio Liases/fisiologia , DNA Glicosilases , DNA Ligases/fisiologia , Reparo do DNA , DNA Fúngico/efeitos dos fármacos , Nucleotídeos de Desoxicitosina/farmacologia , Metanossulfonato de Etila/antagonistas & inibidores , Proteínas Fúngicas/fisiologia , Metilnitronitrosoguanidina/toxicidade , Mutagênese/efeitos dos fármacos , N-Glicosil Hidrolases/fisiologia , Saccharomyces cerevisiae/efeitos dos fármacos , Alquilação , Carbono-Oxigênio Liases/deficiência , Carbono-Oxigênio Liases/genética , Adutos de DNA/metabolismo , Dano ao DNA , DNA Ligases/deficiência , DNA Ligases/genética , Reparo do DNA/efeitos dos fármacos , Reparo do DNA/genética , DNA Fúngico/genética , DNA Fúngico/metabolismo , DNA Liase (Sítios Apurínicos ou Apirimidínicos) , Desoxirribonuclease IV (Fago T4-Induzido) , Metanossulfonato de Etila/toxicidade , Proteínas Fúngicas/genética , Genes Supressores/efeitos dos fármacos , Líquido Intracelular , N-Glicosil Hidrolases/deficiência , N-Glicosil Hidrolases/genéticaRESUMO
The induced expression of c-Myc in plasmacytomas in BALB/c mice is regularly associated with nonrandom chromosomal translocations that juxtapose the c-myc gene to one of the Ig loci on chromosome 12 (IgH), 6 (IgK), or 16 (IgL). The DCPC21 plasmacytoma belongs to a small group of plasmacytomas that are unusual in that they appear to be translocation-negative. In this paper, we show the absence of any c-myc-activating chromosomal translocation for the DCPC21 by using fluorescent in situ hybridization, chromosome painting, and spectral karyotyping. We find that DCPC21 harbors c-myc and IgH genes on extrachromosomal elements (EEs) from which c-myc is transcribed, as shown by c-myc mRNA tracks and extrachromosomal gene transfer experiments. The transcriptional activity of these EEs is supported further by the presence of the transcription-associated phosphorylation of histone H3 (H3P) on the EEs. Thus, our data suggest that in this plasmacytoma, c-Myc expression is achieved by an alternative mechanism. The expression of the c-Myc oncoprotein is initiated outside the chromosomal locations of the c-myc gene, i.e., from EEs, which can be considered functional genetic units. Our data also imply that other "translocation-negative" experimental and human tumors with fusion transcripts or oncogenic activation may indeed carry translocation(s), however, in an extrachromosomal form.
Assuntos
Cadeias Pesadas de Imunoglobulinas/genética , Plasmocitoma/genética , Proteínas Proto-Oncogênicas c-myc/genética , Translocação Genética , Animais , Southern Blotting , Feminino , Regulação da Expressão Gênica , Rearranjo Gênico , Humanos , Camundongos , Camundongos Endogâmicos BALB CRESUMO
1. The metabolism of dexrazoxane (ICRF-187) and its optical isomer levrazoxane (ICRF-186) by the isolated rat hepatocyte was studied by hplc. 2. 4-Chlorobenzenesulphonamide, which is a strong inhibitor of dihydropyrimidine amidohydrolase (DHPase), caused 82% inhibition of the loss of dexrazoxane from the hepatocyte suspension. 3. Dexrazoxane was metabolized at an initial rate by isolated hepatocytes that was 1.8 times faster than levrazoxane. This ratio is close to that found for purified DHPase, suggesting that DHPase present in the hepatocyte catalyses the ring-opening hydrolysis of these drugs. 4. The ratios of the rates at which each of the one-ring open intermediates of dexrazoxane and levrazoxane were produced in the hepatocyte suspension are also consistent with DHPase being primarily responsible for the metabolism of dexrazoxane and levrazoxane. 5. Thus, the DHPase-catalysed formation of the one-ring opened intermediates enhances the rate at which the presumably active metal-ion binding forms of dexrazoxane are produced in the hepatocyte. 6. The DHPase content of the hepatocyte was estimated to be 1.2 nmol/kg of total hepatocyte mass, or equivalently 5700 molecules of DHPase per hepatocyte.
Assuntos
Fígado/metabolismo , Razoxano/metabolismo , Amidoidrolases/antagonistas & inibidores , Amidoidrolases/metabolismo , Animais , Sobrevivência Celular , Cloraminas/farmacologia , Cromatografia Líquida de Alta Pressão , Cinética , Fígado/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-DawleyRESUMO
The receptor for hyaluronan mediated motility (RHAMM) gene expression is markedly elevated in fibrosarcomas exposed to transforming growth factor-beta1 (TGF-beta1). The half-life of RHAMM mRNA was increased by 3 fold in cells treated with TGF-beta1, indicating that growth factor regulation of RHAMM gene expression at least in part involves a posttranscriptional mechanism. Our studies demonstrated that a unique 30-nucleotide (nt) region that has three copies of the sequence, GCUUGC, was the TGF-beta1-responsive region in the 3'-untranslated region (3'-UTR) that mediated message stability. This region interacted specifically with cytoplasmic trans-factors to form multiple protein complexes of approximately 175, 97, 63, 26, and 17 kDa post-TGF-beta1 treatment, suggesting a role for these complexes in the mechanism of action of TGF-beta1-induced message stabilization. Insertion of the 3'-UTR into the chloramphenicol acetyltransferase gene conferred TGF-beta1 induced stability of chloramphenicol acetyltransferase-hybrid RNA in stably transfected cells, while the same insert carrying a deletion containing the 30-nt region had no significant effect on mRNA stability. These results provide a model of RHAMM message regulation in which TGF-beta1-mediated alteration of RHAMM message stability involves the up-regulation of multiple protein interactions with a 30-nt cis-element stability determinant in the 3'-UTR. This model also suggests that this 30-nt base region functions in cis to destabilize RHAMM mRNA in resting normal cells.
Assuntos
Proteínas da Matriz Extracelular/biossíntese , Regulação da Expressão Gênica/efeitos dos fármacos , Receptores de Hialuronatos/biossíntese , RNA Mensageiro/metabolismo , Fator de Crescimento Transformador beta/farmacologia , Animais , Sequência de Bases , Sítios de Ligação , Linhagem Celular , Cloranfenicol O-Acetiltransferase/biossíntese , Fibrossarcoma , Camundongos , Dados de Sequência Molecular , Sondas de Oligonucleotídeos , Oligorribonucleotídeos , Biossíntese de Proteínas/efeitos dos fármacos , RNA Mensageiro/química , Proteínas Recombinantes/biossíntese , Transcrição Gênica , Transfecção , Células Tumorais CultivadasRESUMO
Dexrazoxane (ICRF-187), which is clinically used to reduce doxorubicin-induced cardiotoxicity, has growth inhibitory properties through its ability to inhibit the catalytic activity of DNA topoisomerase II. Because the bisdioxopiperazine dexrazoxane undergoes significant ring-opening hydrolysis under physiological conditions to form two one-ring open hydrolysis intermediates, a study was undertaken to determine if these two intermediates had either any growth inhibitory or topoisomerase II inhibitory effects. Neither of the one-ring open intermediates exhibited growth inhibitory effects towards Chinese hamster ovary cells nor were they able to inhibit topoisomerase II. Thus, it was concluded that only intact dexrazoxane is able to inhibit the catalytic activity of topoisomerase II.
Assuntos
Células CHO/citologia , Fármacos Cardiovasculares/farmacologia , Razoxano/farmacologia , Inibidores da Topoisomerase II , Animais , Células CHO/efeitos dos fármacos , Células CHO/enzimologia , Fármacos Cardiovasculares/química , Fármacos Cardiovasculares/metabolismo , Catálise , Divisão Celular/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão , Cricetinae , DNA Topoisomerases Tipo II/metabolismo , DNA Super-Helicoidal/antagonistas & inibidores , DNA Super-Helicoidal/metabolismo , Hidrólise , Razoxano/química , Razoxano/metabolismoRESUMO
The R2 component of ribonucleotide reductase is rate-limiting for DNA synthesis in proliferating cells, and recently, it has been shown that aberrant expression of R2 directly alters the malignant potential of tumor cells. We show that R2 gene expression is elevated in BALB/c 3T3 cells treated with transforming growth factor (TGF)-beta 1, TGF-beta 2, or TGF-beta 3, as determined by Northern blot analysis. Gel shift assays and UV crosslinking studies demonstrated similar post-transcriptional regulation at the 3'-untranslated region (3'-UTR) of the R2 mRNA, by TGF-beta 1, TGF-beta 2, and TGF-beta 3. The three growth factors induced a common 75 kDa RNA-protein complex. A 9 nucleotide sequence, GAGUUUGAG, previously shown to be responsive to TGF-beta 1-mediated R2 message stability changes, effectively competed out the formation of the R2 3'-UTR complex. We propose that these three different members of the TGF-beta family work through a common mechanism to control an important component of cell proliferation and a potential determinant of malignant progression.